Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001
-
- Lynda M. Vrooman
- Department of Pediatric Oncology, Dana-Farber Cancer Institute,
-
- Traci M. Blonquist
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and
-
- Marian H. Harris
- Department of Pathology, Boston Children’s Hospital, Harvard Medical School, Boston, MA;
-
- Kristen E. Stevenson
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and
-
- Andrew E. Place
- Department of Pediatric Oncology, Dana-Farber Cancer Institute,
-
- Sarah K. Hunt
- Department of Pediatric Oncology, Dana-Farber Cancer Institute,
-
- Jane E. O’Brien
- Department of Pediatric Oncology, Dana-Farber Cancer Institute,
-
- Barbara L. Asselin
- Department of Pediatrics, Golisano Children’s Hospital, University of Rochester School of Medicine and Dentistry, Rochester, NY;
-
- Uma H. Athale
- Division of Pediatric Hematology/Oncology, McMaster University, Hamilton, ON, Canada;
-
- Luis A. Clavell
- Division of Pediatric Oncology, San Jorge Children’s Hospital, San Juan, Puerto Rico;
-
- Peter D. Cole
- Division of Pediatric Hematology/Oncology, Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY;
-
- Kara M. Kelly
- Department of Pediatric Oncology, Roswell Park Cancer Institute, Buffalo, NY;
-
- Caroline Laverdiere
- Division of Hematology and Oncology, Hospital Sainte-Justine, University of Montreal, Montreal, QC, Canada;
-
- Jean-Marie Leclerc
- Division of Hematology and Oncology, Hospital Sainte-Justine, University of Montreal, Montreal, QC, Canada;
-
- Bruno Michon
- Division of Hematology-Oncology, Centre Hospitalier Universitaire de Quebec–Université Laval, Quebec City, QC, Canada;
-
- Marshall A. Schorin
- Inova Fairfax Hospital for Children, Falls Church, VA;
-
- Maria Luisa Sulis
- Division of Pediatric Oncology, Columbia University Medical Center, Morgan Stanley Children’s Hospital of New York–Presbyterian, New York, NY; and
-
- Jennifer J. G. Welch
- Division of Pediatric Hematology-Oncology, Hasbro Children’s Hospital, Warren Alpert Medical School of Brown University, Providence, RI
-
- Donna S. Neuberg
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and
-
- Stephen E. Sallan
- Department of Pediatric Oncology, Dana-Farber Cancer Institute,
-
- Lewis B. Silverman
- Department of Pediatric Oncology, Dana-Farber Cancer Institute,
この論文をさがす
説明
<jats:title>Key Points</jats:title> <jats:p>Childhood B-ALL patients, including those with VHR features, had favorable outcomes on DFCI 05-001 risk-stratified therapy. IKZF1 deletion was an independent predictor of inferior outcome, including among patients with low end-induction MRD.</jats:p>
収録刊行物
-
- Blood Advances
-
Blood Advances 2 (12), 1449-1458, 2018-06-25
American Society of Hematology
